Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · IEX Real-Time Price · USD
177.61
-4.66 (-2.56%)
At close: Jul 2, 2024, 4:00 PM
176.50
-1.11 (-0.62%)
After-hours: Jul 2, 2024, 7:06 PM EDT
Krystal Biotech Revenue
Krystal Biotech had revenue of $95.95M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $45.25M. In the year 2023, Krystal Biotech had annual revenue of $50.70M.
Revenue (ttm)
$95.95M
Revenue Growth
n/a
P/S Ratio
52.86
Revenue / Employee
$418,991
Employees
229
Market Cap
5.07B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 50.70M | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Grifols | 7.32B |
Organon & Co. | 6.35B |
Bausch + Lomb | 4.31B |
DENTSPLY SIRONA | 3.94B |
R1 RCM | 2.31B |
Lantheus Holdings | 1.37B |
Stevanato Group | 1.18B |
Tempus AI | 562.02M |
KRYS News
- 6 weeks ago - Krystal Biotech to Present at the American Thoracic Society 2024 International Conference - GlobeNewsWire
- 7 weeks ago - Krystal Biotech to Present at BofA Securities 2024 Health Care Conference - GlobeNewsWire
- 2 months ago - Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024 - GlobeNewsWire
- 2 months ago - Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung - GlobeNewsWire
- 3 months ago - Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting - GlobeNewsWire
- 4 months ago - Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference - GlobeNewsWire